Navigation Links
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®
Date:11/1/2010

uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective and/or less toxic and effective for the treatment of relapsed or refractory, aggressive NHL and/or other tumors as determined by the EMA, that the EMA may not make a decision on the adoption of the PDCO's recommendations later this quarter, that CTI's MAA submission may not be accepted for review by the EMA by mid-November, that the EMA may not approve CTI's MAA, that the current plans for the PIP may change, that Pixuvri may not prove effective as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive NHL and CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise. Media Contact:Dan Eramian T: 206.272.4343C: 206.854.1200E: deramian@ctiseattle.comwww.CellTherapeutics.com/press_room Investors Contact:Ed BellT: 206.282.7100Lindsey Jesch LoganT: 206.272.4347F: 206.272.4434E: invest@ctiseattle.com www.CellTherapeutics.com/investorsMedical Information Contact:T: 800.715.0944E: info@askarm.com
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015  Victoria Vein & Surgery Clinic ... the Astanza Duality laser in Victoria, Texas ... as well as advanced laser treatments for a variety of ... tattoo industry to provide more services for their patients. Since ... many Victoria residents get rid of ...
(Date:3/27/2015)... Zimmer Holdings, Inc. (NYSE and SIX: ZMH) is celebrating a key milestone ... Complete Knee System. ,   ... first introduced the NexGen knee system, with its innovative design ... implantations of the NexGen knee have taken place worldwide. ... demonstrates the importance of design innovation and component quality for surgeons and ...
(Date:3/27/2015)... , March 27, 2015 Report ... for leading ophthalmic drug companies  What does ... pharma ophthalmic industry ? Visiongain,s brand new report shows ... and prospects there. Our 242-page report provides ... areas in the industry and the future market prospects. ...
Breaking Medicine Technology:Victoria Vein And Surgery Clinic Uses Advanced Astanza Duality Tattoo Removal Technology 2Zimmer Celebrates Key Milestones For NexGen Complete Knee System 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7
... PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - ... 2 clinical,trial results for Hematide(TM) were presented ... in Barcelona, Spain by Iain C.,Macdougall, M.D., ... Macdougall's poster included data in previously-treated,dialysis patients ...
... also Showed Sustained Improvements in Blood Glucose,Control ... 23, 2007 /PRNewswire-FirstCall/ -- Amylin,Pharmaceuticals, Inc. and ... a study that showed BYETTA(R) (exenatide) injection,sustained ... weight,loss through three and a half years ...
Cached Medicine Technology:Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia 2Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 2Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 4Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 5Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 6
(Date:3/29/2015)... 29, 2015 Adults who are comparing ... nationally on the web can now use the QuotesPros.com ... quotes can now be explored while researching the automated ... Learning the differences between what a term policy provides ... challenge for some men and women. Insurers typically provide ...
(Date:3/29/2015)... 29, 2015 The culmination of one of ... when the Final Four invades Lucas Oil Stadium ... been one filled with excitement, buzzer-beaters, and of course, upsets. ... superstars have been made, and future professional products have been ... to the four teams that advanced through their regional bracket ...
(Date:3/29/2015)... NY (PRWEB) March 29, 2015 ... conduct clinical trials and research, manage data results ... help their clients reach regulation standards. Contract research ... and medical device manufacturing sectors. Industry operators provide ... early- to late-stage clinical research for Food and ...
(Date:3/29/2015)... USA (PRWEB) March 29, 2015 ... Link platform provides basic health information around ... opportunity to discuss these challenges as well as ... Health Link addresses six medical conditions using evidenced ... users to engage in conversations around them., ...
(Date:3/29/2015)... California (PRWEB) March 29, 2015 ... a new transition from Pixel Film Studios, entitled TranSports. ... transitions made exclusively for Final Cut Pro X,” said ... our users the tools needed to effortlessly transition using ... introduces TranSports, a new and uniquely styled transition pack ...
Breaking Medicine News(10 mins):Health News:Permanent Life Insurance Quotes Now Offered Through Web Search System at Insurer Website Online 2Health News:Cheap 2015 Final Four Tickets: Ticket Down Slashes Kentucky Wildcats and Wisconsin Badgers Final Four Tickets at Lucas Oil Stadium and Issues Valuable Promo Code 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 3Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2
... latest issues and scientific breakthroughs in nephrology., How: ... related symposia will address this important medical issue., ... Free Communications Highlights:, TH-FC037, ... Blood Pressure. Findings from the National Health and ...
... ... States. VGI will unveil its new VerteLX™ prototypes at the upcoming Congress of Neurological ... ... VG Innovations, Inc (VGI), announced today that its VerteLoc™ Minimally Invasive Spine Stabilization system ...
... Wall posts, photo tags and questionnaires are used ... help friends and families connect; Produce for Kids, ... utilizing Facebook to assess your fresh produce personality. ... Play with Your Produce Personality Quiz helps ...
... Six federally qualified health centers (FQHC) - ... have made the switch to Sage Intergy CHC since July. ... for a fully integrated health center management and electronic health ... FQHC environment and can help these centers qualify for EHR ...
... 20 Nationally-known experts Kenneth J. Doka, PhD, MDiv, ... importance of helping grieving people cope with the holidays ... on Monday, November 16 from 1pm-2pm EST. , "Facing ... with grief during the holidays, traditionally times filled with ...
... , NASHVILLE, Tenn., Oct. 20 Aegis Health ... today that it has entered into an engagement ... Angeles to help the 354-bed facility further strengthen ... , Aegis, Physician Relationship Management program combines the ...
Cached Medicine News:Health News:Press alert for American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition 2Health News:VerteLoc™ Surpasses 750 Procedures....VerteLX™ Prototypes To Be Unveiled at Upcoming CNS Meeting in New Orleans 2Health News:Is Your Fresh Produce Personality Bananas ? 2Health News:FQHC Stigler Health and Wellness Center Chooses Sage Intergy CHC to Meet Unique Reporting Requirements 2Health News:Hospice Foundation of America Presents Webinar on 'Grief, Holidays, and Family Dynamics' 2Health News:Aegis Health Group Tapped by White Memorial Medical Center in Los Angeles to Help Strengthen Local Physician Relationships 2
... Autostat™II Rheumatoid Factor IgM enzyme linked immunosorbent ... (RF IgM). Enzyme-linked immunosorbent assay method for ... Factor in human serum. The results of ... as an aid in the diagnosis of ...
Rheumatoid Factor , R1: 4 X 20 ml buffer, R2: 2 X 8 ml antibody, Test / Kit: 320 (H717)...
... GALILEI Dual Scheimpflug Analyzer is a high ... three dimensional analysis of the anterior eye ... Scheimpflug Camera and a Placido Disk. , ... Placido imaging furnishes high accuracy curvature data, ...
EXTEND is an absorbable synthetic punctal implant that provides occlusion up to three months. It is packaged 20 implants per box in sizes of .0.3mm, 0.4mm, 0.5mm. A variety pack in also available w...
Medicine Products: